Immunotherapy confirmed as standard of care for melanoma brain metastases
Studies also suggest hope for TKI inhibitor combinations in patients with symptomatic brain metastases
Studies also suggest hope for TKI inhibitor combinations in patients with symptomatic brain metastases
Phase I/II trials also show these compounds have more convenient dosing and are well tolerated in both the early and advanced settings
Results from the ATALANTE-1 and MRTX-500 trials show efficacy improvements with immunotherapy in patients post-immune checkpoint inhibitor failure
Adding an immune checkpoint inhibitor to cetuximab plus radiotherapy does not improve outcomes versus standard of care in locally advanced squamous cell carcinoma of the head and neck
Phase III data highlight the consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer patients, with greatest benefit in high PD-L1-expressing tumours
The efficacy and overall good tolerability of cyclin-dependent kinase (CDK) 4/6 inhibitors have led to a change in the therapeutic algorithm of HR-positive/HER2-negative advanced breast cancer and established these compounds as the gold standard option for any patient with metastatic disease, except those with visceral crisis.
Two phase I trials in patients with advanced EGFR-mutated NSCLC demonstrate promising potential of targeted therapy with amivantamab plus lazertinib
Positive in vitro and in vivo antitumour effects in breast and lung cancer models and in mismatch repair-driven cancer models
Significant, but clinically modest, prolongation of radiographic progression-free survival and event-free survival was achieved with darolutamide in the SAKK 08/16 study
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.